$6.20
1.27% yesterday
Nasdaq, Nov 26, 10:00 pm CET
ISIN
US49372L1008
Symbol
KZR

Kezar Life Sciences Inc Stock price

$6.20
+0.01 0.16% 1M
+2.27 57.76% 6M
-0.52 7.74% YTD
-1.23 16.55% 1Y
-67.80 91.62% 3Y
-50.20 89.01% 5Y
-171.30 96.51% 10Y
-171.30 96.51% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
-0.08 1.27%
ISIN
US49372L1008
Symbol
KZR
Industry

Key metrics

Basic
Market capitalization
$45.4m
Enterprise Value
$-47.5m
Net debt
positive
Cash
$100.9m
Shares outstanding
7.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.7
P/B
0.5
Financial Health
Equity Ratio
80.8%
Return on Equity
-71.6%
ROCE
-80.8%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-75.5m | -
EBIT
$-76.5m | $-72.1m
Net Income
$-71.5m | $-60.5m
Free Cash Flow
$-64.2m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
-1.5% | -
EBIT
-1.4% | 19.2%
Net Income
7.5% | 27.7%
Free Cash Flow
19.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-9.8
FCF per Share
$-8.8
Short interest
4.4%
Employees
55
Rev per Employee
$0.0
Show more

Is Kezar Life Sciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

Kezar Life Sciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Kezar Life Sciences Inc forecast:

4x Buy
40%
6x Hold
60%

Analyst Opinions

10 Analysts have issued a Kezar Life Sciences Inc forecast:

Buy
40%
Hold
60%

Financial data from Kezar Life Sciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
8% 8%
-
- Research and Development Expense - -
-
-
-76 -76
2% 2%
-
- Depreciation and Amortization 1.01 1.01
6% 6%
-
EBIT (Operating Income) EBIT -77 -77
1% 1%
-
Net Profit -72 -72
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kezar Life Sciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kezar Life Sciences Inc Stock News

Neutral
Business Wire
15 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a ...
Neutral
Business Wire
20 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two presentations from the completed Phase 2a PORTOLA clinical trial in patients with autoimmune hepatitis (AIH) at The Liver Meeting 2025 held by the American ...
Neutral
Business Wire
about one month ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced regulatory updates and the initiation of a process to explore a full range of strategic alternatives focused on maximizing shareholder value. The C...
More Kezar Life Sciences Inc News

Company Profile

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Christopher Kirk
Employees 55
Founded 2015
Website kezarlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today